A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
NCT00386139
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
881
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Interventions
DRUG:
Aliskiren/HCTZ
Sponsor
Novartis